Clinical Research Directory
Browse clinical research sites, groups, and studies.
Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage
Sponsor: Cell Energy Life Sciences Group Co. LTD
Summary
The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for AIDS patients at late stage.
Official title: A Double-blind, Randomized Placebo-controlled Clinical Trial to Investigate the Safety and Efficacy of Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2023-12-10
Completion Date
2028-07-10
Last Updated
2025-08-12
Healthy Volunteers
No
Conditions
Interventions
mesenchymal stem cell
Mesenchymal stem cell dose is 0.75-1.0×10\*6/kg and is transplanted by intravenous infusion. For the mesenchymal stem cell standard treatment group, the cells are used for three times(at week 0, 2,4 after recruitment) and the mesenchymal stem cell enhanced treatment group, the cells are used for six times(at week 0, 2,4,24,26,28 after recruitment).
saline
saline is used as placebo in the placebo comparator group
Locations (4)
Beijing 302 Hospital
Beijing, China
Beijing YouAn Hospital
Beijing, China
Shenzhen Third People's Hospital
Shenzhen, China
The Fifth Hospital of Shijiazhuang
Shijiazhuang, China